Drug intelligence / Profile preview

HY-0002a

Development stage: Phase 2
Lead developer: Sichuan Huiyu Pharmaceuticals
Modality: Small Molecules

Overview

HY-0002a is a small-molecule inhibitor developed by Huiyu Anlaibo Pharmaceutical Technology, a subsidiary of Sichuan Huiyu Pharmaceutical. It is designed to target specific mutations in the KRAS protein, notably KRAS G12C and KRAS G96D. KRAS is a GTPase that plays a critical role in cell signaling; mutations in this protein are frequent drivers in various cancers, leading to uncontrolled cell proliferation. By inhibiting these mutant forms, HY-0002a aims to disrupt oncogenic signaling pathways. The drug is currently in Phase 1 clinical development for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) and ovarian cancer.

Targets

PI3K (Phosphoinositide-3-kinase regulatory subunit 6)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)

Beyond the preview

Go deeper on HY-0002a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HY-0002a.

Explore the full profile